Biotech Incubators Cultivate a Global Scene
Publication
Article
BioPharm InternationalBioPharm International, Emerging Therapies September 2022
Volume 2022 eBook
Issue 3
Pages: 28–33
The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.
naka/Stock.adobe.com
The life sciences industry is seeing a robust trend in biotech incubator spaces geared toward fostering the growth of new and emerging biotech startups. Incubators on a global scale are determined to grow life sciences innovation in tandem with economically developing local regions. In the United States and other countries, life science sectors around the world are invigorated by efforts on the part of various entities—including government, industry, and academia. Working collectively, these entities aim to foster the growth of burgeoning regional biopharmaceutical industries by providing biotech startups space, talent, funding, and resources.
Read this article in BioPharm International’s September 2022 Emerging Therapies 2022 eBook.
About the author
Feliza Mirasol is the science editor for BioPharm International.
Article Details
BioPharm International
eBook: Emerging Therapies 2022, September 2022
September 2022
Pages: 28–33
Citation
When referring to this article, please cite it as F. Mirasol, “Biotech Incubators Cultivate a Global Scene," BioPharm International Emerging Therapies 2022 eBook (September 2022).
Articles in this issue
Treating Cancer with Oncolytic Viruses
Accelerating the Development of mRNA Therapeutics
Real-Time Post-Apheresis Documentation Decreases Errors
Shining a Light on Lipid Nanoparticle Characterization
The Road to Personalized Medicine: Reimagining Drug Manufacturing
Novel Therapies of 2022
Biotech Incubators Cultivate a Global Scene
Recent Videos
Related Content
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025Article
The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
